Xencor has administered the initial dose to a participant in the Phase 1/2 trial of XmAb®942, aimed at treating inflammatory bowel disease.

HiFiBiO Therapeutics has gained FDA approval for its IND application concerning HFB200604, a leading BTLA agonist antibody.

Sutro Biopharma has launched the REFRαME-P1 Trial to support registration of Luvelta for children with CBF/GLIS AML.

UCB presented Phase 2a findings from the TOGETHER (AH0003) trial, which explored the safety, effectiveness, and tolerability of bepranemab.

AiCuris begins a Phase 1 trial for the antiviral drug AIC468 targeting BK virus infections in kidney transplant patients.

JCR Pharmaceuticals has begun the initial dosing for the Phase I clinical trial of JR-441 targeting Mucopolysaccharidosis Type IIIA.

Numab Therapeutics has begun a Phase 1 clinical trial for the NM32 program targeting patients with solid tumors.

ProMIS Neurosciences Shares Encouraging Results from Phase 1a Trial of PMN310 at the 17th Alzheimer’s Disease Clinical Trials Conference.

Biomea Fusion has released preclinical findings indicating that Icovamenib (BMF-219) improves the efficacy of GLP-1 therapies.

Kither Biotech has revealed the start of a Phase 1 clinical trial for KIT2014, an innovative inhaled peptide treatment for cystic fibrosis.

Avidity Biosciences begins a biomarker group in the FORTITUDE™ trial to seek potential fast-track approval for Delpacibart Braxlosiran (del-brax/AOC 1020).

Akeso has initiated patient recruitment for a Phase 3 study assessing Ivonescimab alongside Ligufalimab (CD47) as a first-line therapy for HNSCC.